[
    {
        "trial_id": "NCT05508789",
        "brief_title": "A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)",
        "official_title": "Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease",
        "lillyAlias": [
            "I5T-MC-AACO"
        ],
        "brief_summary": "The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer Disease",
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders"
        ],
        "drugs_list": [
            "Donanemab",
            "Placebo"
        ],
        "enrollment": 1500,
        "inclusion_criteria": "inclusion criteria: \n\n Gradual and progressive change in memory function reported by the participant or informant for \u22656 months\n A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.\n Meet flortaucipir F18 scan (central read) criteria\n Meet florbetapir F18 scan (central read) criteria\n Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to the study or be available by telephone at designated times.\n A second study partner may serve as backup. The study partner(s) is/are required to accompany the participant for signing consent. The study partner must be present on all days the cognitive and functional scales are administered.\n If a participant has a second study partner, it is preferred that 1 study partner be primarily responsible for the CDR and the ADCS-ADL assessments.\n Days requiring the following assessments and scales must have a study partner available by telephone if not accompanying participant for the following assessments\n\n   AEs and concomitant medications\n   CDR, and\n   ADCS-ADL\n Stable concomitant symptomatic AD medications and other medications that may impact cognition for at least approximately 30 days prior to randomization.",
        "exclusion_criteria": "exclusion criteria: \n\nHas significant neurological disease affect the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of \\<24 months.\nHistory of cancer within the last 5 years, except of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread.\nContraindication to MRI or PET scans",
        "keywords": [
            "Alzheimer's",
            "Dementia",
            "Cognitive Impairment",
            "Amyloid Plaque"
        ]
    },
    {
        "trial_id": "NCT06297590",
        "brief_title": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",
        "official_title": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease",
        "lillyAlias": [
            "J4T-MC-OLAA"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.\n\nThe study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.\n\nThe study will last up to approximately 45 weeks for Part A, and, if conducted, 73 weeks for Part B, including the screening period.\n\nIf the optional bridging period is conducted, participants in Part A could be enrolled in the separate potential study for up to approximately 96 weeks, including the screening period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "LY3954068",
            "Placebo",
            "Flortaucipir F18"
        ],
        "enrollment": 32,
        "inclusion_criteria": "inclusion criteria: \n\n Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.\n Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.\n Have a mini mental state examination (MMSE) score of 18 to 30 at screening.\n Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.\n Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.\n Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).\n Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments.",
        "exclusion_criteria": "exclusion criteria: \n\nHas current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.\nHave a sensitivity to flortaucipir F18.\nHave contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.\nHave previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.\nHave a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture.",
        "keywords": [
            "Dementia",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Tauopathies",
            "Tau",
            "Neurodegenerative Diseases",
            "Neurocognitive Disorders",
            "Mental Disorders",
            "Mild Cognitive Impairment"
        ]
    },
    {
        "trial_id": "NCT05026866",
        "brief_title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)",
        "official_title": "A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease",
        "lillyAlias": [
            "I5T-MC-AACM"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "Donanemab",
            "Placebo"
        ],
        "enrollment": 2196,
        "inclusion_criteria": "inclusion criteria: \n\n A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.\n Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.\n Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.",
        "exclusion_criteria": "exclusion criteria: \n\nMild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.\nCurrent serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately \u22645 years.\nHistory of cancer with high risk of recurrence and preventing completion of the trial.\nHistory of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).\nHave any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.\nHave any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.\nHave a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \\>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.\nHave had prior treatment with a passive anti-amyloid immunotherapy \\<5 half-lives prior to randomization.\nHave received active immunization against amyloid beta (A\u03b2) in any other study.\nHave received active immunization against A\u03b2 in any other study.\nCurrent or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.\n\nAddendum 7 Exclusion Criteria for Clinicaltrials.gov:\n\nSame as the main study except contraindications for florbetapir F 18 PET are exclusionary.",
        "keywords": []
    },
    {
        "trial_id": "NCT06653153",
        "brief_title": "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)",
        "official_title": "A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline",
        "lillyAlias": [
            "J1G-MC-LAKI"
        ],
        "brief_summary": "The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.\n\nParticipation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Alzheimer's Disease"
        ],
        "drugs_list": [
            "Remternetug",
            "Placebo"
        ],
        "enrollment": 1200,
        "inclusion_criteria": "inclusion criteria: \n\n Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.\n Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n Have adequate literacy, vision, and hearing for neuropsychological testing at screening.\n Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.\n Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.\n If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.",
        "exclusion_criteria": "exclusion criteria: \n\nHave dementia or significant other neurological disease that can affect cognition.\nHave current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.\nHave a history of cancer that, in the investigator's opinion, has a high risk of recurrence.\nHave a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.\nHave a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.\nHave any contraindications for magnetic resonance imaging (MRI).\nHave a centrally read MRI that does not meets study entry criteria.\n\nPrior or Current Therapies\n\nHave ever had prior treatment with a passive anti-amyloid immunotherapy.\nHave received active immunization against A\u03b2 in any other study.",
        "keywords": []
    },
    {
        "trial_id": "NCT06566170",
        "brief_title": "A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease",
        "official_title": "Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)",
        "lillyAlias": [
            "I5T-MC-AACS"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.",
        "trial_status": "RECRUITING",
        "phase": {},
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "Donanemab",
            "Usual Care"
        ],
        "enrollment": 3060,
        "inclusion_criteria": "inclusion criteria: \n\nParticipants\n\n are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records \\[EHR\\] is required prior to screening)\n have a Telephone Interview for Cognitive Status (TICS) score of \u226521\n presence of amyloid beta (A\u03b2) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid \\[CSF\\]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)\n have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and\n have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.",
        "exclusion_criteria": "exclusion criteria: \n\nhave prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)\nhave current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (\\>12 months) institutional-level care, serious psychiatric illness, etc.)\nare currently enrolled or intend to enroll in a clinical trial of another investigational product, and\nhave contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).",
        "keywords": []
    },
    {
        "trial_id": "NCT06538116",
        "brief_title": "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease",
        "official_title": "A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease",
        "lillyAlias": [
            "I7S-MC-HBEO"
        ],
        "brief_summary": "The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Alzheimer Disease"
        ],
        "drugs_list": [
            "Mevidalen",
            "Placebo"
        ],
        "enrollment": 300,
        "inclusion_criteria": "inclusion criteria: \n\n Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living.\n Have MMSE score of 13 to 24.\n Have eligibile plasma P-tau or historical evidence of AD pathology.\n Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times.\n Males with partners of childbearing potential must agree to abide with provided contraception guidance.",
        "exclusion_criteria": "exclusion criteria: \n\nAre individuals of childbearing potential.\nHave significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,).\nHave cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities.\nUse of moderate or strong CYP3A4 inhibitors or inducers.\nHave participated within the last 30 days in a clinical trial involving an investigational product.\nParticipant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.",
        "keywords": []
    },
    {
        "trial_id": "NCT06657768",
        "brief_title": "A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)",
        "official_title": "A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD",
        "lillyAlias": [
            "J5K-MC-OQAA"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD).\n\nBlood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThis is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Alzheimer Disease",
            "Healthy"
        ],
        "drugs_list": [
            "LY4006895",
            "Placebo"
        ],
        "enrollment": 68,
        "inclusion_criteria": "inclusion criteria: \n\n ",
        "exclusion_criteria": "exclusion criteria: \n\n ",
        "keywords": []
    },
    {
        "trial_id": "NCT06809400",
        "brief_title": "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease",
        "official_title": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease",
        "lillyAlias": [
            "J5V-MC-ORAA"
        ],
        "brief_summary": "The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Parkinson Disease"
        ],
        "drugs_list": [
            "LY4006896",
            "Placebo"
        ],
        "enrollment": 127,
        "inclusion_criteria": "inclusion criteria: \n\nPart A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD)\n\n Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m\u00b2) (inclusive).\n For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.\n Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.\n\nPart A (SAD) Only\n\n Are overtly healthy\n For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.\n\nPart B (MAD) Only\n\n Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.\n If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.\n If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.\n Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (\u2265) 26.",
        "exclusion_criteria": "exclusion criteria: \n\nPart A (SAD) and B (MAD)\n\nHave significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.\nHave a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.\nHave known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.\nHave significant allergies to humanize monoclonal antibodies.\nHave clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.\nHave history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.\nEvidence of clinically significant anemia.\n\nPart A (SAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.\n\nPart B (MAD) Only\n\nHave an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure \\>150 mm Hg or a diastolic blood pressure \\>95 mm Hg at Screening or Treatment Visits.",
        "keywords": []
    },
    {
        "trial_id": "NCT06220669",
        "brief_title": "A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis",
        "official_title": "An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis",
        "lillyAlias": [
            "J3K-MC-KIAB"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Multiple Sclerosis"
        ],
        "drugs_list": [
            "LY3541860",
            "Placebo"
        ],
        "enrollment": 200,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.\n Participants must have 1 of these:\n\n   at least 1 documented relapse within the previous year\n   at least 2 documented relapses within the previous 2 years, or\n   at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.\n Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (\u2264) 5.5 at screening and randomization.",
        "exclusion_criteria": "exclusion criteria: \n\nHave had a diagnosis of:\n\n  primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or\n  nonactive secondary progressive MS ( Klineova and Lublin 2018).\nMeet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).\nHave a history of clinically significant central nervous system (CNS) disease.\nHave had a confirmed relapse with systemic corticosteroid administration \\<30 days prior to randomization.\nHave more than 20 active GdE brain lesions on screening MRI scan.\nHave received any of these medications or treatments.\nHave a current or recent acute, active infection.\nHave current serious or unstable illnesses.\nHave any other clinically important abnormality at screening or baseline.",
        "keywords": [
            "Relapsing remitting multiple sclerosis, Clinically isolated syndrome, Secondary progressive multiple sclerosis with disease activity."
        ]
    },
    {
        "trial_id": "NCT06553872",
        "brief_title": "Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL",
        "official_title": "A Phase 2, Open-Label, Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in Patients With Relapsed or Refractory Mantle Cell Lymphoma",
        "lillyAlias": [
            "J2N-US-I010"
        ],
        "brief_summary": "This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Mantle Cell Lymphoma"
        ],
        "drugs_list": [
            "Pirtobrutinib",
            "Brexucabtagene Autoleucel"
        ],
        "enrollment": 60,
        "inclusion_criteria": "inclusion criteria: \n\n Patients with a histologically confirmed diagnosis of mantle cell lymphoma (MCL) will be eligible.\n Adult males or females who are 18 years of age or older at time of signing informed consent.\n Must have ability to comprehend and the willingness to sign written informed consent for study participation.\n Eligible to receive CAR T-cell therapy (Brexucabtagene autoleucel) for MCL by the standard of care label, which states: \"TECARTUS or Brexucabtagene autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL)\"\n ECOG performance status 0 to 2.\n Patients are required to have the following washout periods prior to leukapheresis. In addition, prior treatment-related AEs must have recovered to Grade \u2264 1 with the exception of alopecia and Grade 2 peripheral neuropathy.\n\n   Targeted agents (i.e. BTK inhibitors), investigational agents, therapeutic monoclonal antibodies or cytotoxic chemotherapy: 5 half-lives or 2 weeks, whichever is shorter\n   Antibody-drug conjugates (ADC): 10 weeks\n   Radiation therapy: Broad field radiation (\u2265 30% of the bone marrow or whole brain radiotherapy): 14 days. Palliative limited field radiation: 7 days. Note: In the case of known central nervous system (CNS) involvement by systemic lymphoma: Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval.\n   Bendamustine or other purine analogues: 3 months.\n   Corticosteroids: 5 days\n The effects of Pirtobrutinib on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as outlined in criteria below:\n\n   Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow up and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants in their understanding confirmed.\n   Willingness of women of reproductive potential and their partners to observe highly effective birth control methods for the duration of treatment and for 1 month following the last dose of study treatment (see Section 4.3 and Section 4.4 for further details)\n   Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose of pirtobrutinib and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n   Women of non-childbearing potential (i.e. surgically sterile with a hysterectomy and/or bilateral oophorectomy OR \\>= 12 months of amenorrhea) are eligible.\n Patients must meet the following laboratory parameters at screening:\n\n   Hematology (criteria the same regardless of bone marrow involvement; must be independent of transfusions and G-CSF support within 7 days of assessment)\n\n     Platelets \\>= 50 x 10\\^9/L\n     Hemoglobin \\>= 8g/dL\n     Absolute Neutrophil Count \\>=1.0 x 10\\^9/L\n   Hepatic\n\n     ALT \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     AST \\< 2.5 x ULN for age, \\<5 x ULN in the presence of liver metastases\n     Total bilirubin \\< 1.5 x ULN or \\<3 x ULN in the presence of documented Gilbert's syndrome unconjugated hyperbilirubinemia)\n   Renal Creatinine clearance \\>= 30 mL/minute based on Cockcroft-Gault formula.\n   Cardiopulmonary Cardiac LVEF \\>=40% confirmed by ECHO/multigated analysis\n   Adequate pulmonary function \\<= Grade 2 dyspnea and \\<= Grade 2 hypoxia per CTCAE v5.0.\n   Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN.",
        "exclusion_criteria": "exclusion criteria: \n\nPatients who have previously received treatment with pirtobrutinib for \\>2 months prior to study enrollment are ineligible. Patients who are relapsed or refractory and then received less than 2 months of pirtobrutinib as \"holding therapy\" while awaiting CAR T-cell therapy evaluation, and who did not demonstrate disease progression while on pirtobrutinib holding therapy, are eligible.\nPatients who have previously discontinued pirtobrutinib due to disease progression, intolerance, or toxicity.\nPatients who are currently receiving or who have received any investigational study agent \u22644 weeks prior to screening visit are ineligible.\nPrior treatment with chimeric antigen receptor (CAR) T-cell therapy.\nParticipants with clinically significant or uncontrolled cardiac disease, including unstable angina or acute coronary syndrome within the past 2 months prior to randomization, history of myocardial infarction within 3 months prior to randomization, documented LVEF by any method of \u2264 40% in the 12 months prior to randomization, or \u2265 Grade 3 NYHA functional classification system of heart failure.\nUncontrolled or symptomatic arrhythmias, including prolongation of the QT interval corrected for heart rate (QTcF) \\> 470 msec. QTcF is calculated using Fridericia's Formula (QTcF): QTcF = QT/(RR0.33). Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation. Correction for underlying bundle branch block (BBB) allowed. Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker\nEvidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.\nParticipants with active immunologic or inflammatory/autoimmune disease affecting the CNS, and unrelated to their disease under study or previous treatment.\nPatients with active CNS involvement of Mantle Cell Lymphoma. A history of CNS Mantle Cell Lymphoma is allowed, as long as it has cleared, and the patient is able to comply with study procedures. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible with documented Sponsor approval.\nKnown positive Human immunodeficiency virus (HIV) status. For patients with unknown HIV status, HIV testing will be performed at Screening and result must be negative for enrollment.\nHepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require a negative hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are HBV DNA PCR positive will be excluded. Patients who are HBV DNA PCR negative with positive anti-HBc require prophylaxis against Hepatitis B reactivation (see Section 6.4 \"General Guidance for Hepatic Monitoring\").\nHepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be excluded.\nKnown active cytomegalovirus (CMV) infection. Unknown or negative status are eligible.\nParticipants who require the concurrent use of chronic systemic steroids or immunosuppressant medications. Steroids should not be given within 5 days prior to leukapheresis. Concomitant bridging steroids (section 6.6) are allowed after leukapheresis.\nKnown hypersensitivity or severe reaction to pirtobrutinib, similar compounds, or excipients.\nParticipants who have not recovered from adverse events (AEs) due to prior anticancer therapy (i.e., have residual toxicities \\> Grade 1), with the exception of stable Grade 2 peripheral neuropathy and/or any grade alopecia.\nPregnant or nursing (breast-feeding) women are excluded from this study because there is an unknown but potential risk to using pirtobrutinib in pregnant or nursing women. Patients are excluded if they are pregnant or plan to become pregnant during the study or within 1 year of the last dose of study treatment. Patients are also excluded if they are lactating or plan to breastfeed during the study or within 1 week of the last dose of study treatment. Please see Section 4.3 and Section 4.4 for General Guidance for Women of Child Bearing Potential and/or Use of Contraceptive Methods.\nAny condition that would, in the investigator's judgement, interfere with full participation in the study, including administration of pirtobrutinib and attending required study visits (if outpatient); pose a significant risk to the participant; or interfere with interpretation of study data.\nInability of the participant to swallow and retain oral medication. Or, if there is clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drug.\nPatients who experienced a major bleeding event or grade \u2265 3 arrhythmia on prior treatment with a BTK inhibitor. NOTE: Major bleeding is defined as bleeding having one or more of the following features: potentially life-threatening bleeding with signs or symptoms of hemodynamic compromise; bleeding associated with a decrease in the hemoglobin level of at least 2g per deciliter; or bleeding in a critical area or organ (e.g., retroperitoneal, intraarticular, pericardial, epidural, or intracranial bleeding or intramuscular bleeding with compartment syndrome)\nMajor surgery within 4 weeks prior to enrollment.\nHistory of a previously diagnosed hereditary bleeding disorder.\nPatients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist.\nActive second malignancy unless in remission and with life expectancy \\> 2 years.\nVaccination with live vaccine within 28 days prior to randomization.\nHistory of stroke or intracranial hemorrhage within 6 months of enrollment.\nHistory of allogeneic or autologous stem cell transplant within 60 days of enrollment, presence of either of the following regardless of prior stem cell transplant timing: active graft vs. host disease; cytopenias from incomplete blood cell count recovery post-transplant.\nActive uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts.",
        "keywords": []
    }
]